Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:s33-s38
Published online before print January 3, 2008, doi: 10.1161/ATVBAHA.107.160689
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/3/s33    most recent
ATVBAHA.107.160689v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michelson, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michelson, A. D.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:s33.)
© 2008 American Heart Association, Inc.


Translational Therapeutics at the Platelet Vascular Interface: A CME-Certified Activity

P2Y12 Antagonism

Promises and Challenges

Alan D. Michelson

From the Center for Platelet Function Studies, Departments of Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester.

Correspondence to Alan D. Michelson, MD, Director, Center for Platelet Function Studies, University of Massachusetts Medical School, Room S5-846, 55 Lake Avenue North, Worcester, MA 01655. E-mail michelson{at}platelets.org

The P2Y12 antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo. Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials.


Key Words: platelets • clopidogrel • prasugrel • AZD6140 • cangrelor




This article has been cited by other articles:


Home page
Cereb CortexHome page
S. Amadio, C. Montilli, R. Magliozzi, G. Bernardi, R. Reynolds, and C. Volonte
P2Y12 Receptor Protein in Cortical Gray Matter Lesions in Multiple Sclerosis
Cereb Cortex, September 26, 2009; (2009) bhp193v1.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Stefanini, R. C. Roden, and W. Bergmeier
CalDAG-GEFI is at the nexus of calcium-dependent platelet activation
Blood, September 17, 2009; 114(12): 2506 - 2514.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med, September 1, 2009; 71(7): 741 - 747.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. D. Michelson, A. L. Frelinger III, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, et al.
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
Eur. Heart J., July 2, 2009; 30(14): 1753 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. Veverka and J. M. Hammer
Prasugrel: A New Thienopyridine Inhibitor
Journal of Pharmacy Practice, April 1, 2009; 22(2): 158 - 165.
[Abstract] [PDF]